NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Forecast & News

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

Five Prime Therapeutics Inc (NASDAQ:FPRX) posted its earnings results on Wednesday, November, 6th. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.95) by $0.08. The biotechnology company had revenue of $2.98 million for the quarter, compared to the consensus estimate of $4.33 million. Five Prime Therapeutics had a negative return on equity of 65.39% and a negative net margin of 921.30%. View Five Prime Therapeutics' Earnings History.

Five Prime Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Five Prime Therapeutics.

Five Prime Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

5 brokers have issued twelve-month price targets for Five Prime Therapeutics' stock. Their forecasts range from $5.00 to $24.00. On average, they expect Five Prime Therapeutics' share price to reach $12.25 in the next year. This suggests a possible upside of 128.5% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Five Prime Therapeutics.

News coverage about FPRX stock has been trending somewhat positive recently, InfoTrie reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Five Prime Therapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Five Prime Therapeutics.

Five Prime Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,710,000 shares, an increase of 14.0% from the January 15th total of 1,500,000 shares. Based on an average daily trading volume, of 488,500 shares, the days-to-cover ratio is currently 3.5 days. Currently, 4.8% of the company's stock are short sold. View Five Prime Therapeutics' Current Options Chain.

Some companies that are related to Five Prime Therapeutics include Basilea Pharmaceutica (BPMUF), Urogen Pharma (URGN), Flexion Therapeutics (FLXN), BioXcel Therapeutics (BTAI), Molecular Templates (MTEM), XBiotech (XBIT), ZIOPHARM Oncology (ZIOP), Arcus Biosciences (RCUS), AC Immune (ACIU), Ardelyx (ARDX), Puma Biotechnology (PBYI), Assembly Biosciences (ASMB), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA) and Neoleukin Therapeutics (NLTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Novavax (NVAX), Opko Health (OPK), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD) and Amarin (AMRN).

Five Prime Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (21.39%), Renaissance Technologies LLC (4.84%), State Street Corp (1.72%), Man Group plc (1.50%), Geode Capital Management LLC (1.42%) and AQR Capital Management LLC (1.23%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View Institutional Ownership Trends for Five Prime Therapeutics.

FPRX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Assenagon Asset Management S.A., AXA, UBS Group AG, State Street Corp, Citigroup Inc., Bank of New York Mellon Corp and Algert Global LLC. View Insider Buying and Selling for Five Prime Therapeutics.

FPRX stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Russell Investments Group Ltd., Platinum Investment Management Ltd. and Geode Capital Management LLC. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Five Prime Therapeutics.

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FPRX stock can currently be purchased for approximately $5.36.

Five Prime Therapeutics has a market capitalization of $195.06 million and generates $49.87 million in revenue each year. The biotechnology company earns $-140,450,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe.View Additional Information About Five Prime Therapeutics.

The official website for Five Prime Therapeutics is http://www.fiveprime.com/.

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]